Cefixime + Ofloxacin Tablets Manufacturer & Exporter

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness exports Cefixime + Ofloxacin Tablets for bacterial illnesses requiring enhanced oral antibacterial coverage against enteric and respiratory pathogens. The formulation is commonly selected in typhoid fever, urinary tract infections, lower respiratory infections, and gastrointestinal bacterial disorders where broader-spectrum therapy is recommended.

Ofloxacin acts rapidly on bacterial DNA enzymes involved in bacterial multiplication, while Cefixime provides prolonged cephalosporin antibacterial action against susceptible organisms. As a recognized Advanced Oral Antibiotic Manufacturer, Genliva Wellness develops combination antibacterial tablets intended for outpatient infection management and broader pathogen control.

Operating as a Cefixime Ofloxacin Tablets Exporter, Genliva Wellness LLP supplies combination antibiotic formulations to pharmaceutical distributors and international healthcare supply chains.

Cefixime + Ofloxacin Tablets are developed for broader-spectrum oral antibacterial therapy.

Cephalosporin and fluoroquinolone tablet combination
Preferred in enteric and respiratory infections
Supports wider bacterial coverage
Optimized oral antibacterial formulation
Manufactured under stringent quality standards
Suitable for outpatient antibacterial therapy

This formulation is widely used in bacterial infection treatment protocols.

Treatment of typhoid fever
Management of urinary tract infections
Used in lower respiratory bacterial conditions
Prescribed in gastrointestinal bacterial disorders
Supports bacterial eradication in mixed infections
Used in advanced oral antibacterial therapies

Cefixime + Ofloxacin Tablets provide dual antibacterial action for difficult bacterial conditions.

Useful in enteric fever management
Helps control respiratory bacterial complications
Supports wider antibacterial effectiveness
Convenient oral treatment option
Combines cephalosporin and fluoroquinolone activity